No benefit of induction chemo, high-dose boost in anal cancer

April 26, 2012
No benefit of induction chemo, high-Dose boost in anal cancer

(HealthDay) -- Neither induction chemotherapy (ICT) nor high-dose radiation boost is associated with an improvement in five-year colostomy-free survival (CFS) in patients with locally advanced anal canal carcinoma (LAACC), according to a study published online April 23 in the Journal of Clinical Oncology.

To investigate whether dose escalation of the radiation boost or two cycles of ICT before radiotherapy would improve CFS, Didier Peiffert, M.D., Ph.D., of the Centre Alexis Vautrin in Vandoeuvre-le`s-Nancy, France, and colleagues conducted a involving 307 patients with LAACC tumors. Patients were randomly allocated to four treatment arms: two ICT cycles, radiochemotherapy, and standard-dose boost (A); two ICT cycles, radiochemotherapy, and high-dose boost (B); radiochemotherapy and standard-dose boost (C); and radiochemotherapy with high-dose boost (D).

The researchers found that 283 patients completed the full treatment. After a median follow-up period of 50 months, the five-year CFS rates in the four treatment arms were 69.6, 82.4, 77.1, and 72.7 percent for arms A, B, C, and D, respectively. There was no significant ICT effect (comparing groups A and B with C and D) or boost-dose effect (A and C versus B and D).

"Using CFS as our main end point, we did not find an advantage for either ICT or high-dose radiation boost in LAACC," the authors write. "Nevertheless, the results of the most treatment-intense arm B should prompt the design of further intensification studies."

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Higher radiation dose does not help lung cancer patients live longer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

Researchers thwart cancer cells by triggering 'virus alert'

August 27, 2015

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.